83-2272-49　［受注停止］KRIBIOLISA Obrindatamab ELISA 1 x 96 wells　KBI1763

特徴

• Description：ELISA for the detection of bispecific antibody Obrindatamab in human serum and plasma.
• Lead time for this kit is 5 weeks.
• About the kit： - Uses anti-idiotypic monoclonal antibodies sourced from our vendor partner in the US, which ensures higher specificity, and low cross reactivity.
• - Recovery rates are between 85 - 115％ - Validated as per US FDA guidelines for Bioassays - Developed using the innovator drug as calibrator - Shelf life： 1 year.Obrindatamab is an activating bispecific molecule that binds to both B7-H3 （CD276） and CD3, therefore bringing the targeted B7-H3-expressing cells together with T-cells, resulting in cytotoxic immune response.
• Upon administration of the drug, the anti-B7-H3 component targets and binds to the cell surface antigen B7-H3; at the same time, the anti-CD3 component binds to human CD3.
• This cross-links the T cells to B7-H3-expressing tumor cells, activates and redirects endogenous T cells to kill B7-H3-expressing tumor cells, and inhibits proliferation of B7-H3-expressing tumor cells.